Molecular Evidence Demonstrating Local Treatment Failure is the Source of Distant Metastases in Some Patients Treated for Breast Cancer

International Journal of Radiation Oncology Biology Physics

Volumn 71, Issue 3, 2008, Pages 689-694

  Vicini, Frank A ^a   Goldstein, Neal S ^a   Wallace, Michelle ^a   Kestin, Larry ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

Breast conserving therapy; Local recurrence; Loss of heterozygosity; Lumpectomy; Radiotherapy; Survival

Indexed keywords

ENZYME ACTIVITY; MOLECULAR STRUCTURE; TUMORS;

DISTANT METASTASIS (DM); INVASIVE BREAST CARCINOMA (IBC); IPSILATERAL BREAST FAILURE (IBF);

RADIOTHERAPY;

ADULT; ALLELIC IMBALANCE; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER CONTROL; CANCER RECURRENCE; CLINICAL ARTICLE; CLONAL VARIATION; CONTROLLED STUDY; DISTANT METASTASIS; GENE MUTATION; HUMAN; IPSILATERAL BREAST FAILURE; LOCAL THERAPY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TREATMENT FAILURE;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MIDDLE AGED; TREATMENT FAILURE; TUMOR MARKERS, BIOLOGICAL;

EID: 44449093939     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2008.02.045     Document Type: Article

References (23)

1. Fisher E.R., Anderson S., Tan-Chiu E., et al. Fifteen-year prognostic discriminants for invasive breast carcinoma. Cancer 91 (2001) 1679-1687
2. Fowble B. Ipsilateral breast tumor recurrence following breast-conserving surgery for early-stage invasive cancer. Acta Oncol 38 Suppl. 13 (1999) 9-17
3. Punglia R.S., Morrow M., Winer E.P., et al. Local therapy and survival in breast cancer. N Engl J Med 356 (2007) 2399-2405
4. Veronesi U., Marubini E., Del Vecchio M., et al. Local recurrences and distant metastases after conservative breast cancer treatments: partly independent events. J Natl Cancer Inst 87 (1995) 19-27
5. Wapnir I.L., Anderson S.J., Mamounas E.P., et al. Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials. J Clin Oncol 24 (2006) 2028-2037
6. Fortin A., Larochelle M., Laverdiere J., et al. Local failure is responsible for the decrease in survival for patients with breast cancer treated with conservative surgery and postoperative radiotherapy. J Clin Oncol 17 (1999) 101-109
7. Overgaard M., Jensen M.B., Overgaard J., et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet 353 (1999) 1641-1648
8. Overgaard M., Hansen P.S., Overgaard J., et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy: Danish Breast Cancer Cooperative Group 82b trial. N Engl J Med 337 (1997) 949-955
9. Ragaz J., Jackson S.M., Le N., et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med 337 (1997) 956-962
10. Clarke M., Collins R., Darby S., et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials. Lancet 366 (2005) 2087-2106
11. Kollias J., Man S., Marafie M., et al. Loss of heterozygosity in bilateral breast cancer. Breast Cancer Res Treat 64 (2000) 241-251
12. Kung F.Y., Tse G.M., Lo K.W., et al. Metachronous bilateral mammary metaplastic and infiltrating duct carcinomas: A molecular study for clonality. Hum Pathol 33 (2002) 677-679
13. Lininger R.A., Fujii H., Man Y.G., et al. Comparison of loss heterozygosity in primary and recurrent ductal carcinoma in situ of the breast. Mod Pathol 11 (1998) 1151-1159
14. Schlechter B.L., Yang Q., Larson P.S., et al. Quantitative DNA fingerprinting may distinguish new primary breast cancer from disease recurrence. J Clin Oncol 22 (2004) 1830-1838
15. Bianchi A.B., Navone N.M., and Conti C.J. Detection of loss of heterozygosity in formalin-fixed paraffin-embedded tumor specimens by the polymerase chain reaction. Am J Pathol 138 (1991) 279-284
16. Kini V.R., White J.R., Horwitz E.M., et al. Long term results with breast-conserving therapy for patients with early stage breast carcinoma in a community hospital setting. Cancer 82 (1998) 127-133
17. Goldstein N.S., Vicini F.A., Hunter S., et al. Molecular clonality determination of ipsilateral recurrence of invasive breast carcinomas after breast-conserving therapy: Comparison with clinical and biologic factors. Am J Clin Pathol 123 (2005) 679-689
18. Sieben N.L., Kolkman-Uljee S.M., Flanagan A.M., et al. Molecular genetic evidence for monoclonal origin of bilateral ovarian serous borderline tumors. Am J Pathol 162 (2003) 1095-1101
19. Elston C.W., and Ellis I.O. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology 19 (1991) 403-410
20. Sorlie T., Perou C.M., Tibshirani R., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98 (2001) 10869-10874
21. Sorlie T. Molecular portraits of breast cancer: Tumour subtypes as distinct disease entities. Eur J Cancer 40 (2004) 2667-2675
22. abd El-Rehim D.M., Ball G., Pinder S.E., et al. High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer 116 (2005) 340-350
23. Lichy J.H., Dalbegue F., Zavar M., et al. Genetic heterogeneity in ductal carcinoma of the breast. Lab Invest 80 (2000) 291-301